Application of fermentation lactobacillus mucus A6-3 in preparation of helicobacter pylori inhibition product

Through the combined application of Lactobacillus mucinous A6-3 and licorice extract, the high drug resistance rate and gastrointestinal flora imbalance in the treatment of Helicobacter pylori infection were solved, significantly reducing Helicobacter pylori colonization and inflammatory response, and improving the Treatment effects and abundance of gut probiotics.

CN119033827APending Publication Date: 2024-11-29GUIZHOU MEDICAL UNIV

Patent Information

Application Number
CN202411336358.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-24
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The prior art has problems with high drug resistance, gastrointestinal flora disorders and poor patient compliance when treating Helicobacter pylori infection. The clearance rate of probiotics to Helicobacter pylori is limited. There is no report on the combined use of Chinese herbal medicines and probiotics. .

Method used

The combined application of Lactobacillus fermented mucosa A6-3 and licorice extract was used to significantly reduce Helicobacter pylori colonization through Lactobacillus fermented mucosa A6-3, and enhance its effect of inhibiting Helicobacter pylori colonization and inflammatory response through licorice extract.

Benefits of technology

Significantly reduce Helicobacter pylori colonization, improve the inflammatory response caused by Helicobacter pylori, improve the therapeutic effect of Helicobacter pylori infection, and enhance the abundance of intestinal probiotics through combined use, and improve gastrointestinal flora disorders.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033827A_ABST
    Figure CN119033827A_ABST
Patent Text Reader

Abstract

The invention provides application of fermented lactobacillus mucus A6-3 in preparation of a product for inhibiting helicobacter pylori, and belongs to the technical field of biological medicine. The fermented lactobacillus mucus A6-3 can significantly reduce helicobacter pylori colonization and improve inflammatory response induced by helicobacter pylori. Meanwhile, the invention also provides an application of the lactobacillus mucus A6-3 combined with the licorice extract in preparation of a product for inhibiting helicobacter pylori, and the A6-3 combined with the licorice extract can significantly enhance inhibition of helicobacter pylori colonization and inflammatory response induced by helicobacter pylori by the A6-3. The invention provides thinking and theoretical basis for treatment of helicobacter pylori infection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and in particular relates to an application of fermented mucus lactobacillus A6-3 in the preparation of a product for inhibiting Helicobacter pylori. Background Art

[0002] Helicobacter pylori (Hp) is a pathogen that colonizes on human gastric mucosal epithelial cells. Helicobacter pylori is the cause of many diseases such as gastritis and peptic ulcer. At present, the treatment of Helicobacter pylori infection is still mainly based on triple antibiotic therapy, bismuth-containing quadruple therapy, and sequential therapy. However, antibiotic treatment has brought about problems such as increasing resistance, gastrointestinal flora imbalance, and poor patient compliance. It is reported that probiotics have a direct or indirect inhibitory effect on Helicobacter pylori and can improve the flora imbalance caused by antibiotics, but their clearance rate for Helicobacter pylori is limited. In addition, the calendula in the Chinese herbal medicine calendula can relieve chronic atrophic gastritis (CAG) caused by Helicobacter pylori, and the clove water extract can inhibit the growth and adhesion of Helicobacter pylori. Licorice (Glycyrrhiza uralensisFisch.) is a plant of the Leguminosae family and the genus Glycyrrhiza, which has the effects of tonifying the spleen and replenishing qi, clearing away heat and detoxifying, removing phlegm and relieving cough, relieving acute pain, and harmonizing various medicines. Therefore, there is an urgent need to obtain a probiotic strain that can effectively eliminate Helicobacter pylori, and there are no reports on the combination of probiotic strains and Chinese herbal medicines for inhibiting Helicobacter pylori. Summary of the invention

[0003] In view of this, the object of the present invention is to provide an application of fermented Lactobacillus mucilaginosus A6-3 in the preparation of a product for inhibiting Helicobacter pylori.

[0004] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0005] The invention provides an application of fermented Lactobacillus mucosa A6-3 in preparing a product for inhibiting Helicobacter pylori. The preservation number of the fermented Lactobacillus mucosa A6-3 is CGMCC No.27257.

[0006] The present invention provides an application of fermented Lactobacillus mucosa A6-3 in preparing a product for treating diseases caused by Helicobacter pylori infection. The preservation number of the fermented Lactobacillus mucosa A6-3 is CGMCC No.27257.

[0007] Preferably, the disease includes one or more of gastritis, digestive tract inflammation and ulcer.

[0008] The invention provides an application of fermented mucus lactobacillus A6-3 combined with liquorice extract in preparing a product for inhibiting Helicobacter pylori. The preservation number of the fermented mucus lactobacillus A6-3 is CGMCC No.27257.

[0009] Preferably, the preparation method of the licorice extract comprises: soaking and slicing licorice to obtain licorice slices, mixing the licorice slices with water and boiling them to obtain a decoction, allowing the decoction to settle, and concentrating the supernatant to obtain the licorice extract.

[0010] Preferably, the solvent used for penetration is water; the mass volume ratio of the licorice slices to water is 1g:90-110mL; the number of decoctions is 2-4 times, and the decoction time is 1.5-2.5h.

[0011] The invention provides an application of fermented mucus lactobacillus A6-3 combined with liquorice extract in preparing a product for treating diseases caused by Helicobacter pylori infection. The preservation number of the fermented mucus lactobacillus A6-3 is CGMCC No.27257.

[0012] Preferably, the disease includes one or more of gastritis, digestive tract inflammation and ulcer; and the licorice extract is the licorice extract prepared by the above preparation method.

[0013] The present invention also provides a medicine for inhibiting Helicobacter pylori, comprising the fermented mucus lactobacillus A6-3 and the liquorice extract.

[0014] The present invention also provides an application of fermented mucus lactobacillus A6-3 combined with licorice extract in the preparation of a product for preventing and treating intestinal flora disorder caused by Helicobacter pylori infection or improving intestinal probiotics after Helicobacter pylori infection.

[0015] Compared with the prior art, the present invention has the following beneficial effects:

[0016] The present invention provides an application of fermented mucus lactobacillus A6-3 in the preparation of a product for inhibiting Helicobacter pylori, and the fermented mucus lactobacillus A6-3 can significantly reduce the colonization of Helicobacter pylori and improve the inflammatory response induced by Helicobacter pylori. At the same time, the present invention also provides an application of fermented mucus lactobacillus A6-3 combined with licorice extract in the preparation of a product for inhibiting Helicobacter pylori, and A6-3 combined with licorice extract can significantly enhance the inhibition of A6-3 on the colonization of Helicobacter pylori and the inflammatory response induced by Helicobacter pylori. The present invention provides a new idea and theoretical basis for the treatment of Helicobacter pylori infection. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 is the content of Helicobacter pylori antibody in the mouse serum after treatment in different groups, including A: blank control group, B: model group, C: positive control group, D: licorice group, E: A6-3 group, F: A6-3 + licorice group. Compared with the blank control group, P # <0.05; compared with the model group, P *<0.05; compared with A6-3+licorice group, P & <0.05; compared with the positive control group, P @ <0.05;

[0018] Figure 2 is the number of immune cells in the whole blood of mice after treatment with different groups, a is the number of leukocytes in the whole blood of mice after treatment with different groups, b is the number of lymphocytes in the whole blood of mice after treatment with different groups, c is the number of intermediate cells in the whole blood of mice after treatment with different groups, d is the number of granulocytes in the whole blood of mice after treatment with different groups, among which, A: blank control group, B: model group, C: positive control group, D: licorice group, E: A6-3 group, F: A6-3 + licorice group, compared with the blank control group, P # <0.05; compared with the model group, P * <0.05; compared with A6-3+licorice group, P & <0.05;

[0019] Figure 3 is the content of serum inflammatory markers in mice after treatment with different groups, a is the comparison result of LPS concentration in serum after treatment with different groups, b is the comparison result of CRP concentration in serum after treatment with different groups, c is the comparison result of IL-1β concentration in serum after treatment with different groups, d is the comparison result of IL-6 concentration in serum after treatment with different groups, e is the comparison result of TNF-α concentration in serum after treatment with different groups, f is the comparison result of IL-4 concentration in serum after treatment with different groups, g is the comparison result of IL-10 concentration in serum after treatment with different groups, h is the comparison result of PGⅠ concentration in serum after treatment with different groups, i is the comparison result of PGⅡ concentration in serum after treatment with different groups; A: blank control group, B: model group, C: positive control group, D: licorice group, E: A6-3 group, F: A6-3 + licorice group, compared with the blank control group, P # <0.05; compared with the model group, P * <0.05; compared with A6-3+licorice group, P & <0.05; compared with the positive control group, P @ <0.05;

[0020] Figure 4 HE staining of gastric tissue pathology in different groups (100 μm, 100×), where A: blank control group, B: model group, C: positive control group, D: licorice group, E: A6-3 group, F: A6-3 + licorice group, a indicates inflammatory cell infiltration, b indicates epithelial cell shedding, c indicates glandular structure disorder, and d indicates mucosal congestion;

[0021] Figure 5The composition and relative abundance of the intestinal flora of mice after treatment in different groups, a is the composition and relative abundance of the intestinal flora at the phylum level; b is the composition and relative abundance of the intestinal flora at the genus level; c is the relative abundance of Akkermansia at the genus level. The significant differences between the two groups are marked as: ** P<0.01. DETAILED DESCRIPTION

[0022] The invention provides an application of fermented Lactobacillus mucosa A6-3 in preparing a product for inhibiting Helicobacter pylori. The preservation number of the fermented Lactobacillus mucosa A6-3 is CGMCC No.27257.

[0023] In the present invention, the fermented mucus lactobacillus A6-3 is isolated from folk fermented glutinous rice (laozao) in Guizhou Province through MRS culture medium, and was deposited in the General Microbiology Center (CGMCC) of the China Microbiological Culture Collection Administration Committee on May 4, 2023, at No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing. The product includes a drug or a vaccine. The active ingredient of the drug is fermented mucus lactobacillus A6-3, and the drug can ferment mucus lactobacillus A6-3 as the only active ingredient, or fermented mucus lactobacillus A6-3 can be used in combination with other drugs that inhibit Helicobacter pylori. In the present invention, the mass ratio of the fermented mucus lactobacillus A6-3 to the drug is more than 50%. The drug also includes pharmaceutically acceptable excipients, and the excipients include one or more of excipients, flavoring agents or preservatives.

[0024] The present invention provides an application of fermented Lactobacillus mucosa A6-3 in preparing a product for treating diseases caused by Helicobacter pylori infection. The preservation number of the fermented Lactobacillus mucosa A6-3 is CGMCC No.27257.

[0025] In the present invention, the diseases include one or more of gastritis, digestive tract inflammation and ulcer. The present invention has found that A6-3 and A6-3 combined with licorice extract can inhibit Helicobacter pylori, reduce the number of white blood cells in the whole blood of mice and the concentration of pro-inflammatory markers LPS, CRP, IL-6, TNF-α, IL-1β in serum, and increase the concentration of anti-inflammatory factors IL-4 and IL-10, and reduce the mRNA expression levels of IL-6, IL-1β, TNF-α, COX-2 and STAT3 in gastric mucosal tissue, and the concentration of gastritis markers PGⅠ and PGⅡ, and improve diseases caused by Helicobacter pylori infection.

[0026] The invention provides an application of fermented mucus lactobacillus A6-3 combined with liquorice extract in preparing a product for inhibiting Helicobacter pylori. The preservation number of the fermented mucus lactobacillus A6-3 is CGMCC No.27257.

[0027] In the present invention, the preparation method of the licorice extract comprises: soaking and slicing licorice to obtain licorice slices, mixing the licorice slices with water and boiling them to obtain a decoction, allowing them to settle, and concentrating the supernatant to obtain the licorice extract. The licorice refers to the medicinal parts of licorice: the root and rhizome of licorice.

[0028] When preparing licorice extract, the solvent used for penetration is water; the mass volume ratio of the licorice slices to water is preferably 1g:90-110mL; the number of decoctions is preferably 2-4 times, more preferably 3 times, and the decoction time is preferably 1.5-2.5h, more preferably 2h.

[0029] The present invention provides an application of fermented mucus lactobacillus A6-3 combined with liquorice extract in preparing a product for treating diseases caused by Helicobacter pylori infection. The preservation number of the fermented mucus lactobacillus A6-3 is CGMCC No.27257.

[0030] In the application of the fermented mucus lactobacillus A6-3 combined with licorice extract, the disease includes one or more of gastritis, digestive tract inflammation and ulcer; the licorice extract is the licorice extract prepared by the above preparation method.

[0031] The present invention also provides a medicine for inhibiting Helicobacter pylori, comprising the fermented mucus lactobacillus A6-3 and the liquorice extract.

[0032] In the above-mentioned drug for inhibiting Helicobacter pylori, the concentration of the fermented mucus lactobacillus A6-3 is 3 to 5×10 8 CFU, the content of the licorice extract is 0.8-1.2g.

[0033] The present invention also provides an application of fermented mucus lactobacillus A6-3 combined with licorice extract in the preparation of a product for preventing and treating intestinal flora disorder caused by Helicobacter pylori infection or improving intestinal probiotics after Helicobacter pylori infection.

[0034] In the present invention, the intestinal probiotics include Akkermansia muciniphila.

[0035] The present invention utilizes fermented mucus lactobacillus A6-3 combined with liquorice extract to significantly enhance the effect of A6-3 in treating Helicobacter pylori, and has a synergistic effect.

[0036] In the present invention, unless otherwise specified, all raw material components are commercially available products well known to those skilled in the art.

[0037] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0038] In the following examples, the fermented mucus lactobacillus A6-3 has a deposit number of CGMCC No. 27257 and is deposited in the General Microbiology Center of the China National Committee for the Administration of Microbiological Culture Collection.

[0039] The Helicobacter pylori is derived from Daoyan Wu # ;Mei Cao # ; Jie Zhou; Shiying Yan; Jingshan Peng; Zhihao Yu; Andong Zhang; Jialin Wu; Xin Yan; Jian Zhao * ; Helicobacter pylori recorded in Lactobacillus caseiT1 from kurut against Helicobacter pylori-induced inflammation and the gut microbial disorder, Journal of Functional Foods, 2021, 85C:104611.

[0040] Example 1

[0041] 1.1 Experimental methods

[0042] 1.1.1 Preparation of experimental materials

[0043] (1) Preparation of licorice extract: soak licorice with water and slice into 0.2 cm thick slices to obtain licorice slices; mix 1 g of licorice slices with 100 mL of water and boil for 2 h; collect the first decoction and the first decoction slices; mix 1 g of the first decoction slice with 100 mL of water and boil for 2 h; collect the second decoction and the second decoction slices; mix 1 g of the second decoction slice with 100 mL of water and boil for 2 h; collect the third decoction; combine the first decoction, the second decoction and the third decoction to obtain the total decoction; leave overnight to allow the second decoction to precipitate; take the supernatant and concentrate it into a thick paste to obtain licorice extract.

[0044] (2) Cultivation of Helicobacter pylori and preparation of bacterial suspension for oral administration: Helicobacter pylori strains frozen at -80°C were revived and subcultured for 2 to 3 generations. 1 mL of sterile saline was added to the subcultured plate, and the colonies were scraped off with a spreader stick. The concentration of the bacterial suspension was adjusted to 2 × 10 9 CFU / mL, and obtain Helicobacter pylori liquid.

[0045] (3) Cultivation of Lactobacillus mucilaginosus A6-3 and preparation of bacterial suspension for gavage: The A6-3 strain stored in a -80°C refrigerator was revived and subcultured. The subcultured A6-3 bacterial suspension was centrifuged at 6000 rpm for 10 min, and the supernatant was discarded. After washing twice with physiological saline, the bacterial suspension concentration was adjusted to 2×10 9 CFU / mL, and obtain A6-3 bacterial suspension.

[0046] 1.1.2 Experimental grouping, modeling, medication, and sample collection

[0047] (1) Experimental grouping and modeling: 63 BALB / c SPF mice, 6-8 weeks old, male, weighing 18-22 g, were randomly divided into a blank control group (A, 10 mice) and a modeling group (53 mice) after one week of adaptive feeding. Each mouse in the modeling group was given 0.2 mL of NaHCO3 to neutralize gastric acid. One hour later, mice were given 2×10 9 0.2 mL of fresh Helicobacter pylori liquid with CFU / mL was orally gavaged, and the blank control group was orally gavaged with an equal amount of sterile saline, once every other day, for a total of 7 times. All mice were fasted and deprived of water for 12 hours before gavage, and fasted and deprived of water for 2 hours after gavage. Two days after the last infection with Helicobacter pylori, 3 mice were randomly selected from the modeling group to detect Helicobacter pylori. After verifying that the modeling was successful, the mice were randomly divided into the model group (B), positive control group (C), licorice group (D), A6-3 group (E) and A6-3 + licorice group (F), of which the licorice group had 9 mice and the other groups had 10 mice each.

[0048] (2) Treatment: The blank control group and the model group were given sterile saline 0.2 mL / d, the positive drug group was given clarithromycin 90 mg / kg·d, the licorice group was given licorice extract 540 mg / kg·d, and the A6-3 group was given 2×10 9 CFU / mL of A6-3 suspension 0.2mL, the combined treatment group was given licorice extract 540mg / kg·d and the concentration of each administration was 2×10 9 0.2 mL of A6-3 bacterial suspension with CFU / mL was administered once a day for 14 consecutive days.

[0049] (3) Sample collection: According to the requirements of the Experimental Animal Ethics Committee, mice were killed by cervical dislocation after anesthesia. Whole blood and serum were collected for routine blood tests and ELISA tests, respectively. Three gastric tissues were collected: one for rapid urease detection, one stored in 4% paraformaldehyde for HE staining, and one for RNA extraction for RT-qPCR testing. At the same time, the intestinal contents of each group were collected after treatment.

[0050] 1.1.3 Effect of licorice extract, probiotic A6-3, and licorice extract combined with A6-3 on the clearance of Helicobacter pylori in mouse gastric mucosa

[0051] Analysis of Helicobacter pylori infection: The positive situation of Helicobacter pylori was directly detected by rapid urease test paper and the level of Helicobacter pylori antibody (Helicobacter pylori-Ab) in serum was detected by enzyme-linked immunosorbent assay (ELISA) to analyze the clearance of Helicobacter pylori.

[0052] The results of the rapid urease test for the positive status of Helicobacter pylori in different groups are shown in Table 1.

[0053] Table 1 Urease test results

[0054]

[0055] In Table 1, “-” indicates Helicobacter pylori negative, and “+” indicates Helicobacter pylori positive.

[0056] The results in Table 1 show that the administration of licorice extract, probiotic A6-3, licorice extract combined with A6-3 and clarithromycin reduced the load of Helicobacter pylori in the gastric mucosal tissue of mice. Figure 1 The results showed that licorice extract, probiotic A6-3, licorice extract combined with A6-3 and clarithromycin reduced the level of serum Helicobacter pylori IgG resistance, and the content in the A6-3 + licorice group was significantly lower than that in the A6-3 alone treatment group. The above results suggest that licorice extract, A6-3 and A6-3 + licorice extract combined use are effective in clearing Helicobacter pylori, and A6-3 combined with licorice extract can increase the clearance rate of Helicobacter pylori.

[0057] 1.1.4 Effects of licorice extract, probiotic A6-3, and licorice extract combined with A6-3 on the content of immune cells in the blood of mice induced by Helicobacter pylori infection

[0058] Routine blood test to detect the number of immune cells in the blood: The whole blood collected from each group of mice was used to measure the number of mouse white blood cells, lymphocytes, neutrophils, etc. according to the requirements of the blood cell analyzer.

[0059] Figure 2The results showed that the levels of white blood cells, lymphocytes and granulocytes in the blood of mice were increased after infection with Helicobacter pylori. After treatment with licorice extract, probiotic A6-3, licorice extract combined with A6-3 and clarithromycin, the four types of immune cells could be reduced to varying degrees. There was no significant difference in the therapeutic effects of the licorice group, A6-3 group and A6-3 + licorice group compared with the positive control group, and the combined treatment of A6-3 + licorice group had a better effect on white blood cells and lymphocytes than the licorice group using licorice extract alone. The results showed that licorice extract, A6-3 and A6-3 combined with licorice extract all had an effect on reducing the inflammatory response of mice, and the effect was consistent with the trend of clarithromycin treatment, and the effect of A6-3 combined with licorice extract was better than that of licorice extract and A6-3 alone.

[0060] 1.1.5 Effects of licorice extract, probiotics A6-3, and licorice extract combined with A6-3 on the levels of inflammatory markers in the blood of mice induced by Helicobacter pylori infection

[0061] ELISA detection of serum inflammatory marker levels: Take out the frozen serum, and according to the instructions of the kit, detect the levels of inflammatory markers LPS, CRP, IL-1β, IL-6, TNF-α, IL-4, IL-10, PGⅠ and PGⅡ in mouse serum.

[0062] Figure 3 The results showed that after Helicobacter pylori infection in mice, the levels of LPS, CRP, IL-1β, IL-6, TNF-α and PGⅡ increased, and the expression of anti-inflammatory factors IL-4, IL-10 and PGⅠ decreased. Licorice extract, probiotic A6-3, licorice extract combined with A6-3 and clarithromycin treatment reduced the levels of LPS, CRP, IL-1β, IL-6, TNF-α and PGⅡ, and the levels of anti-inflammatory factors IL-4, IL-10 and PGⅠ increased to varying degrees. In addition, the concentrations of CRP, IL-1β, LPS, TNF-α and PGⅡ in licorice extract combined with A6-3 were significantly lower than those in the A6-3 treatment group alone, and the concentrations of IL-4, IL-10 and PGⅠ in licorice extract combined with A6-3 were significantly higher than those in the A6-3 treatment group alone.

[0063] 1.1.6 Effects of licorice extract, probiotic A6-3, and licorice extract combined with A6-3 on the inflammatory response of gastric mucosal tissue in mice infected with Helicobacter pylori

[0064] RT-qPCR detection of inflammatory factor expression in gastric mucosal tissue: gastric mucosal tissue of mice was taken, total RNA was extracted by TRIZOL method, and the expression of each gene was detected by RT-qPCR after reverse transcription. The primer sequences are shown in Table 2. The amplification program was: 95℃5min; 95℃30s, 58℃30s, 72℃50s, a total of 50 cycles; 72℃8min, and it was automatically completed in the program set by the fluorescence quantitative PCR instrument. The data were obtained using 2 -ΔΔCt The relative expression of the target gene relative to the internal reference gene was calculated.

[0065] Table 2 RT-qPCR primer sequences

[0066]

[0067] Table 3 Expression levels of mRNA of inflammatory indicators in gastric mucosal tissue of mice

[0068] Group IL-6 IL-1β TNF-α COX-2 STAT3 Blank control group 1.00±0.00 1.00±0.00 1.00±0.00 1.00±0.00 1.00±0.00 Model Group 1.35±0.48 1.63±1.12 <![CDATA[2.25±0.57 # ]]> <![CDATA[1.74±0.76 # ]]> 1.60±1.20 Licorice group <![CDATA[0.44±0.25 *& ]]> <![CDATA[0.28±0.16 * ]]> <![CDATA[0.59±0.33 * ]]> <![CDATA[0.48±0.28 * ]]> <![CDATA[0.60±0.33 * ]]> Positive control group 1.14±0.34 0.73±0.13 <![CDATA[0.75±0.28 * ]]> <![CDATA[0.61±0.33 * ]]> 0.75±0.28 A6-3 Group 0.78±0.63 <![CDATA[0.16±0.08 * ]]> 1.52±1.37 <![CDATA[0.64±0.74 * ]]> <![CDATA[0.40±0.13 * ]]> A6-3+Licorice Group <![CDATA[0.46±0.41 *& ]]> <![CDATA[0.65±0.84 * ]]> <![CDATA[0.93±0.49 * ]]> <![CDATA[0.54±0.36 * ]]> 0.86±0.59

[0069] The results are shown in Table 3. The relative mRNA expression levels of TNF-α and COX-2 in the model group were higher than those in the blank control group (P<0.05). Compared with the model group, the relative mRNA expression levels of IL-6, IL-1β, TNF-α, COX-2 and STAT3 in the licorice group, TNF-α and COX-2 in the positive control group, IL-1β, COX-2 and STAT3 in the A6-3 group, and IL-6, IL-1β, TNF-α, and COX-2 in the A6-3+licorice group were lower than those in the model group (P<0.05), and the A6-3+licorice group was lower than the A6-3 group. The above results show that clarithromycin, licorice extract, A6-3, and A6-3 combined with licorice extract can reduce the expression level of inflammatory factors in gastric mucosal tissue of mice and have an effect on improving inflammation caused by Helicobacter pylori infection; the effect of the A6-3+licorice group is better than that of the A6-3 treatment group alone.

[0070] 1.1.7 HE staining to evaluate the pathological changes of gastric tissue in mice induced by Helicobacter pylori infection induced by licorice extract, probiotics A6-3, and licorice extract combined with A6-3

[0071] HE staining was used to examine the pathological changes of gastric tissue in mice: the gastric tissue of mice fixed in 4% paraformaldehyde was embedded in paraffin and 5 μm thin sections were cut. After staining with hematoxylin-eosin (HE staining), a slice scanner was used to observe the inflammatory cell infiltration and gastric mucosal morphology of the mouse gastric mucosa.

[0072] Figure 4 The results showed that the stomach tissue structure of mice in the blank control group was intact, the glands were neatly arranged, and there was no shedding of gastric mucosal epithelial cells, edema, or congestion ( Figure 4A in Figure 1). Compared with the blank control group, the gastric glandular structure of the mice in the model group was disordered, the gastric mucosa was severely congested, a large number of epithelial cells were shed, and obvious inflammatory cell infiltration was observed ( Figure 4 B in the figure). Compared with the model group, the gastric mucosal injury status of the clarithromycin treatment group, the licorice extract or A6-3 alone treatment group, and the A6-3 + licorice group was significantly improved, the gastric mucosal epithelial cell shedding, gastric mucosal congestion and glandular structure disorder were alleviated, and the inflammatory cell infiltration was reduced ( Figure 4 The above data show that licorice extract, probiotics A6-3, and licorice extract combined with A6-3 have an improving effect on gastric mucosal injury induced by Helicobacter pylori infection in mice.

[0073] 1.1.8 Effects of licorice extract, probiotic A6-3, and licorice extract combined with A6-3 on intestinal flora of mice induced by Helicobacter pylori infection

[0074] The 16S rRNA sequencing of the microbiota was completed by Microecology Biotechnology Company, and all intestinal microbiota sequencing results and bioinformatics analysis were completed on the Microecology Alliance Biotechnology Cloud Platform (https: / / www.bioincloud.tech).

[0075] ① DNA extraction and PCR amplification

[0076] (1) After collecting the intestinal contents of each group, they were immediately frozen in liquid nitrogen.

[0077] (2) The DNA of the sample was extracted using the cetyl trimethyl ammonium bromide method (CTAB). After extraction, the purity and concentration of the DNA were detected by 1% agarose gel electrophoresis. The remaining DNA template was placed in a thin-walled tube and the sample was diluted to 1 ng / μL using sterile water. The DNA template was amplified by PCR using primers.

[0078] (3) The PCR products were detected by 2% agarose electrophoresis.

[0079] ②Sequencing analysis

[0080] (1) After the PCR products were mixed evenly, they were purified using 2% agarose gel electrophoresis (Qiagen gel recovery kit) and then the target band was recovered.

[0081] (2) The DNA library was constructed using the Illumina library construction kit (TruSeq DNA PCR-Free Sample Preparation Kit). The constructed library was subjected to Qubit quantification and library detection. Once it met the standards, it was sequenced using an instrument (NovaSeq 6000PE250).

[0082] ③Information analysis

[0083] (1) Use the qiime tools import plug-in to import the original sequence fastq file into a file format that can be processed by QIIME2.

[0084] (2) Then use the QIIME2 dada2 plug-in to process and obtain the required data.

[0085] (3) The obtained sequences were compared using the QIIME2 feature-classifier plug-in to obtain a species classification information table.

[0086] (4) ANCOM and ANOVA methods were used to identify bacteria with different abundances among groups and samples.

[0087] like Figure 5 As shown in the figure, the intestinal microorganisms in the intestines of C57BL / 6J mice in the seven treatment groups were mainly divided into eight phyla at the phylum level, among which Firmicutes had the highest relative abundance. Helicobacter pylori infection reduced the relative ratio of Firmicutes to Bacteroidetes. Clarithromycin, A6-3 and licorice extract treatment increased the relative ratio of Firmicutes to Bacteroidetes. Helicobacter pylori infection reduced the relative abundance of Verrucomicrobia, while clarithromycin, A6-3 and licorice extract treatment did not increase the relative abundance of Verrucomicrobia, but the combined treatment of A6-3 and licorice extract increased the relative abundance of Akkermansia. At the genus level, the relative abundance of Akkermansia was the highest in the combined treatment group of A6-3 and licorice extract. Treatment with A6-3 and licorice alone did not increase the relative abundance of Akkermansia, which was consistent with the change in the relative abundance of Verrucomicrobia (Akkermansia belongs to the Verrucomicrobia phylum), indicating that A6-3 combined with licorice can promote the relative abundance of Akkermansia in the intestine.

[0088] Akkermansia has the functions of regulating immune responses in the spleen, intestines and mesenteric lymph nodes and reducing the level of inflammation in the intestine, which suggests that A6-3 and licorice extract may exert anti-Helicobacter pylori infection effects by synergistically promoting the growth of Akkermansia and then regulating host immunity.

[0089] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Application of fermented mucus lactobacillus A6-3 in the preparation of products for inhibiting Helicobacter pylori, It is characterized in that The deposit number of the fermented mucus lactobacillus A6-3 is CGMCC No.27257.

2. Application of fermented Lactobacillus mucilaginosus A6-3 in the preparation of products for treating diseases caused by Helicobacter pylori infection, It is characterized in that The deposit number of the fermented mucus lactobacillus A6-3 is CGMCC No.27257.

3. The use according to claim 2, It is characterized in that The disease includes one or more of gastritis, digestive tract inflammation and ulcer.

4. Application of fermented mucus lactobacillus A6-3 combined with licorice extract in the preparation of products for inhibiting Helicobacter pylori, It is characterized in that The deposit number of the fermented mucus lactobacillus A6-3 is CGMCC No.27257.

5. The use according to claim 4, It is characterized in that The preparation method of the licorice extract comprises: soaking and slicing licorice to obtain licorice slices, mixing the licorice slices with water and boiling to obtain a decoction, allowing to settle, and concentrating the supernatant to obtain the licorice extract.

6. The use according to claim 5, It is characterized in that The solvent used for penetration is water; the mass volume ratio of the licorice slices to water is 1g:90-110mL; the number of decoctions is 2-4 times, and the decoction time is 1.5-2.5h.

7. Application of fermented mucus lactobacillus A6-3 combined with licorice extract in the preparation of products for treating diseases caused by Helicobacter pylori infection, It is characterized in that The deposit number of the fermented mucus lactobacillus A6-3 is CGMCC No.27257.

8. The use according to claim 7, It is characterized in that The diseases include one or more of gastritis, digestive tract inflammation and ulcer; the licorice extract is the licorice extract as claimed in claim 5 or 6.

9. A drug for inhibiting Helicobacter pylori, It is characterized in that The invention comprises the fermented mucus lactobacillus A6-3 as claimed in claim 1 and the liquorice extract as claimed in claim 5 or 6.

10. Application of fermented mucus lactobacillus A6-3 combined with licorice extract in the preparation of intestinal probiotic products for preventing and treating intestinal flora disorders caused by Helicobacter pylori infection or improving intestinal probiotics after Helicobacter pylori infection.

Citation Information

Patent Citations

  • Composition with auxiliary protection effect on gastric mucosal injury and application

    CN112641097A

  • Inactivated probiotic traditional Chinese medicine composition for inhibiting helicobacter pylori as well as preparation method and application of inactivated probiotic traditional Chinese medicine composition

    CN113577218A

  • Strain composition, application of strain composition, affine cudweed probiotic fermentation product and preparation method of affine cudweed probiotic fermentation product

    CN117025459A

  • Lactobacillus mucilaginosus and application thereof in improving infectious gastritis

    CN118421541A

Cited By

  • Composition with helicobacter pylori resisting effect and preparation method thereof

    CN119999918A

  • Dog and cat pet fungicide compound as well as preparation method and application thereof

    CN122381949A